Full-Time

Associate Director

Market Access Strategy, T1D

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$173.5k - $260.2k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

3 days onsite, 2 days remote weekly.

Category
Business Research
Strategy Development
Business & Strategy
Requirements
  • Knowledge of US payer coverage, hospital reimbursement and CMS policies; hospital or CGT experience a plus
  • Ability to translate clinical data into economic messages
  • Marketing or other relevant strategic planning and execution skills including: positioning, branding, project management, and working collaboratively with agencies and vendors – recent Managed markets experience preferred
  • Ability to perform in a fast-paced environment, manage multiple priorities simultaneously, and work effectively across cross-functional teams
  • Proven track record of meeting or exceeding objectives & goals, both as an individual and as part of a team
  • Excellent communication skills with experience presenting to customers and internal leadership
  • US Product launch experience a must
  • Bachelor’s degree in relevant field
  • Typically requires 8+ years of MA experience or the equivalent combination of education and experience
Responsibilities
  • Develop US market access strategies and tactical plans to support the upcoming T1D program, flawlessly executing key Payer, hospital and Trade initiatives to secure rapid and broad access
  • Lead initiatives to understand, analyze and demonstrate the clinical, economic and societal value to payers, hospitals, decision-makers and influencers; collaborate with GIACO to plan and implement market research
  • Co-create resources to support field pull-through engagement with HCPs
  • Assist in the design and build out of the value story across payer and trade channels
  • Lead capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving payer environment
  • Support the Market Access Field Organization in customer segmentation strategy, planning and execution (eg training, account management tools/resources, and POA needs)
  • Manage day-to-day agency and vendor workflow to ensure resources are delivered on time & w/in budget
  • Instrumental in brand planning activities; plan and execute Payer/Trade ad boards
  • Accountable for CRM requirements and insight mining, CRC reviews, Customer Facing Talking points and establishment of launch KPIs
  • Define and establish Trade resources in tandem with Trade field leadership
  • Act as trusted, subject matter expert on US payer landscape to internal colleagues and externally facing customers
Desired Qualifications
  • Hospital or CGT experience a plus
  • Recent Managed markets experience preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).